Differential in vitro metabolism of β-endorphin in schizophrenia

Hans Schoemaker, Thomas P Davis

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Biologically active peptide fragments derived from the proteolytic cleavage of β-endorphin (βE) have been shown to be present in the brain. Based on clinical results using some of these fragments in neuropsychiatric disease studies we investigated the in vitro metabolism of βE by twice-washed membrane homogenates of postmortem putamen from sex and age matched controls versus subjects with a diagnosis of schizophrenia. The present study demonstrates that frozen (-80°C) postmortem human tissues are viable for these studies and that metabolism in control tissue proceeds similarly to fresh tissues. Furthermore, a significant increase in the formation of the putative neuroleptic-like peptide fragment desenkephalin-γ-endorphin in postmortem schizophrenic putamen versus controls was shown. A significant decrease in the formation of βE 6-21 was also reported. These data suggest that an approach using postmortem human brain is possible in studying β-endorphin catabolism and is therefore applicable to other neuropeptide systems.

Original languageEnglish (US)
Pages (from-to)1049-1054
Number of pages6
JournalPeptides
Volume5
Issue number6
DOIs
StatePublished - 1984

Fingerprint

Endorphins
Metabolism
Schizophrenia
Peptide Fragments
Putamen
Tissue
Brain
Neuropeptides
Antipsychotic Agents
Membranes
In Vitro Techniques

Keywords

  • High performance liquid chromatography
  • Proteolytic processing
  • Schizophrenia
  • α-Endorphin
  • β-Endorphin
  • γ-Endorphin

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Physiology
  • Cellular and Molecular Neuroscience

Cite this

Differential in vitro metabolism of β-endorphin in schizophrenia. / Schoemaker, Hans; Davis, Thomas P.

In: Peptides, Vol. 5, No. 6, 1984, p. 1049-1054.

Research output: Contribution to journalArticle

Schoemaker, Hans ; Davis, Thomas P. / Differential in vitro metabolism of β-endorphin in schizophrenia. In: Peptides. 1984 ; Vol. 5, No. 6. pp. 1049-1054.
@article{d1164d25007947b99e08623c0722395e,
title = "Differential in vitro metabolism of β-endorphin in schizophrenia",
abstract = "Biologically active peptide fragments derived from the proteolytic cleavage of β-endorphin (βE) have been shown to be present in the brain. Based on clinical results using some of these fragments in neuropsychiatric disease studies we investigated the in vitro metabolism of βE by twice-washed membrane homogenates of postmortem putamen from sex and age matched controls versus subjects with a diagnosis of schizophrenia. The present study demonstrates that frozen (-80°C) postmortem human tissues are viable for these studies and that metabolism in control tissue proceeds similarly to fresh tissues. Furthermore, a significant increase in the formation of the putative neuroleptic-like peptide fragment desenkephalin-γ-endorphin in postmortem schizophrenic putamen versus controls was shown. A significant decrease in the formation of βE 6-21 was also reported. These data suggest that an approach using postmortem human brain is possible in studying β-endorphin catabolism and is therefore applicable to other neuropeptide systems.",
keywords = "High performance liquid chromatography, Proteolytic processing, Schizophrenia, α-Endorphin, β-Endorphin, γ-Endorphin",
author = "Hans Schoemaker and Davis, {Thomas P}",
year = "1984",
doi = "10.1016/0196-9781(84)90169-4",
language = "English (US)",
volume = "5",
pages = "1049--1054",
journal = "Peptides",
issn = "0196-9781",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Differential in vitro metabolism of β-endorphin in schizophrenia

AU - Schoemaker, Hans

AU - Davis, Thomas P

PY - 1984

Y1 - 1984

N2 - Biologically active peptide fragments derived from the proteolytic cleavage of β-endorphin (βE) have been shown to be present in the brain. Based on clinical results using some of these fragments in neuropsychiatric disease studies we investigated the in vitro metabolism of βE by twice-washed membrane homogenates of postmortem putamen from sex and age matched controls versus subjects with a diagnosis of schizophrenia. The present study demonstrates that frozen (-80°C) postmortem human tissues are viable for these studies and that metabolism in control tissue proceeds similarly to fresh tissues. Furthermore, a significant increase in the formation of the putative neuroleptic-like peptide fragment desenkephalin-γ-endorphin in postmortem schizophrenic putamen versus controls was shown. A significant decrease in the formation of βE 6-21 was also reported. These data suggest that an approach using postmortem human brain is possible in studying β-endorphin catabolism and is therefore applicable to other neuropeptide systems.

AB - Biologically active peptide fragments derived from the proteolytic cleavage of β-endorphin (βE) have been shown to be present in the brain. Based on clinical results using some of these fragments in neuropsychiatric disease studies we investigated the in vitro metabolism of βE by twice-washed membrane homogenates of postmortem putamen from sex and age matched controls versus subjects with a diagnosis of schizophrenia. The present study demonstrates that frozen (-80°C) postmortem human tissues are viable for these studies and that metabolism in control tissue proceeds similarly to fresh tissues. Furthermore, a significant increase in the formation of the putative neuroleptic-like peptide fragment desenkephalin-γ-endorphin in postmortem schizophrenic putamen versus controls was shown. A significant decrease in the formation of βE 6-21 was also reported. These data suggest that an approach using postmortem human brain is possible in studying β-endorphin catabolism and is therefore applicable to other neuropeptide systems.

KW - High performance liquid chromatography

KW - Proteolytic processing

KW - Schizophrenia

KW - α-Endorphin

KW - β-Endorphin

KW - γ-Endorphin

UR - http://www.scopus.com/inward/record.url?scp=0021706783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021706783&partnerID=8YFLogxK

U2 - 10.1016/0196-9781(84)90169-4

DO - 10.1016/0196-9781(84)90169-4

M3 - Article

VL - 5

SP - 1049

EP - 1054

JO - Peptides

JF - Peptides

SN - 0196-9781

IS - 6

ER -